Advertisement
YOU ARE HERE: LAT HomeCollectionsBreast Cancer
IN THE NEWS

Breast Cancer

SCIENCE
February 18, 2014 | By Melissa Healy, This post has been corrected, as indicated below.
A team of researchers from the City of Hope in Duarte has developed a speedy way to identify drugs and chemicals that can disrupt the balance of sex hormones in human beings and influence the development and progress of diseases such as breast cancer. In a trial screening of 446 drugs in wide circulation, the new assay singled out the popular antidepressant paroxetine (better known by its commercial name, Paxil) as having a weak estrogenic effect that could promote the development and growth of breast tumors in women.
Advertisement
NEWS
July 26, 2011 | By Karen Kaplan, Los Angeles Times/For the Booster Shots blog
Women with early-stage breast cancer have plenty of procedures and treatments to deal with. So it may come as welcome news that a large clinical trial has found no reason for doctors to perform two tests that were thought to help predict patient survival. Writing in the Journal of the American Medical Assn., the researchers say that the test results are meaningless. The tests in question involve looking for micrometastasis - microscopic evidence of a breast tumor's spread - in sentinel lymph nodes and in bone marrow.
NEWS
October 28, 2010 | By Mary Forgione, Los Angeles Times
For many women, the fight against breast cancer is public, with support from friends and family and frequent discussions with healthcare professionals about side effects and treatment. But part of that fight is intensely private -- rarely more so than when it affects their sex life. Certain chemotherapy drugs send women into early menopause within a few months. That, coupled, with hair loss and disfiguring mastectomies, leave some breast cancer survivors struggling to be intimate again, a new study finds.
NEWS
December 10, 2010 | By Shari Roan, Los Angeles Times
The breast cancer drug pertuzumab when added to Herceptin improved the treatment of women with early-stage, HER-2 positive breast cancer, researchers reported Friday at the annual meeting of the San Antonio Breast Cancer Symposium . Pertuzumab is an experimental monoclonal antibody. In the study, 417 women received monoclonal antibody drug therapy before having surgery to remove the tumor. Some women also underwent chemotherapy. Adding pertuzumab to Herceptin -- which is also known by the generic name trastuzumab -- along with the chemotherapy drug docetaxel led to a tumor eradication rate of 46%. That is 50% better than the tumor eradication rate achieved with the standard therapy of docetaxel and Herceptin combined, said the authors of the paper, from the National Cancer Institute in Milan, Italy.
NEWS
September 30, 2010 | Pregnant breast cancer patients more likely to survive
There may be few pregnancy nightmares worse than finding a lump in one's breast, given the dueling fears that if it's cancer, treatment could harm the developing fetus, while delay and pregnancy hormones could fuel a tumor's growth. But a new study finds that pregnant women treated for breast cancer are more likely to survive their ordeal than breast cancer patients of the same age who were not pregnant when their cancer was diagnosed. Five years after their diagnosis, almost 74% of the women diagnosed with breast cancer during pregnancy were still alive.
HEALTH
January 26, 2009 | Marc Siegel, Siegel is an internist and an associate professor of medicine at New York University's School of Medicine.
"Nip/Tuck" FX, season premiere: Jan. 6 and 13, 10 p.m. The premise Plastic surgeon Dr. Christian Troy (Julian McMahon) takes his associate Dr. Liz Cruz (Roma Maffia) for a mammogram because he thinks he felt a lump in her breast. The test is negative but, while at the radiologist's office, Troy admits that he himself has felt a lump in his own chest.
NEWS
November 28, 2012 | By Jon Bardin
A new genetic test may help determine whether a small tumor in the breast is likely to turn in to full-blown breast cancer, according to a study published Wednesday in the Journal of the National Cancer Institute. The small tumor, called a ductal carcinoma in-situ, or DCIS, resides in the milk ducts and is generally considered pre-cancerous. But according to the study, DCIS lesions left untreated will eventually progress to breast cancer in about 50% of patients. The lesions, which tend to be small and only detectable via mammogram, have become increasingly common as mammography has become more widespread.
Los Angeles Times Articles
|